The pathogenesis of Alzheimer's disease (AD) involves a key event which changes the morphology of amyloid-β 42 (Aβ 42 ) peptide from its soluble monomeric form into the fibrillated aggregates in the brain. Aluminum ion, Al(III), is known to act as a pathological chaperone of the Aβ 42 in this process; curcumin, a natural phenolic compound, is considered capable of binding Al(III) and Aβ 42 ; nevertheless, little is known about the combined action of curcumin and Al(III) on the Aβ 42 fibrillation and neurotoxicity. Here, combinations of circular dichroism spectroscopy, thioflavin T fluorescence, atomic force microscopy, Bradford and MTT assays, it is demonstrated that although Al(III) can promote the Aβ 42 fibrillation dose-dependently, leading to the high neurotoxicity to PC12 cells, curcumin can inhibit the events. Besides, we found that curcumin is able not only to inhibit the formation of Al(III)-induced Aβ 42 fibrillation, but also to form the Al(III)-curcumin complexes which in turn can remold the preformed, mature, ordered Aβ 42 fibrils into the low toxic amorphous aggregates. These findings suggest that curcumin could block the binding of Al(III) with Aβ 42 and form the Al(III)-curcumin complexes, so as to inhibit the Al(III)-induced Aβ 42 fibrillation and neurotoxicity. The Al(III)-curcumin complexes are worth potentially developing as a therapy agent against the neurodegenerative disorders in the future.
Introduction
Amyloid plaques and neurofibrillary tangles, containing amyloidβ (Aβ) peptides and tau proteins respectively, are conceived as two pathological hallmarks of Alzheimer's disease (AD). The progressive accumulation of Aβ aggregates via a fibrillation process is widely believed fundamental to initialize the neurodegenerative pathology and trigger a cascade of events which include neurotoxicity, oxidative stress and inflammation during the progression of AD [1] [2] [3] . The Aβ fibrillation involves the dimer and oligomer formation, and their growth into the protofibrils and fibrils via a complicated multistepnucleated polymerization process [4] . Nowadays, the emerging role of soluble entities, oligomers, in the neurodegenerative disorders is widely accepted, putting aside the old idea which considers that the fibrils and neuritic plaques are the primary entities responsible for the disease [5, 6] . Accordingly, new attempts have been carried out to search for the therapeutic agents which can inhibit the formation of toxic oligomers and remold the preformed fibrils into non-toxic components instead of toxic fibril precursors [7] . Nonetheless, only limited experimental results of those agents have been reported and the action mechanism of the agents is still ambiguous.
Some metal ions have been demonstrated as the potential risk cofactors in the neurodegenerative disorders [8, 9] . These metal ions, such as Fe 3 + , Al 3 + , accelerate the dynamic process of Aβ aggregation, thus enhancing the neurotoxicity on the neuronal cells, as a consequence of marked alterations of biophysical properties of the peptide [9] [10] [11] . It is worth noticing that among those metal ions, Al(III), absorbed or accumulated in human body via diet, antacids, cosmetics, fumes and particles from the occupational exposure [12] , is a component in the senile plaques and suggested promoting Aβ aggregation and increasing Aβ neurotoxicity efficiently [13] [14] [15] . It is evidenced that Al(III) accumulated in AD brain accelerates the generation of Aβ peptide due to the faulty proteolysis of normal amyloid precursor protein [16, 17] , meanwhile, Al(III) inhibits the proteolytic degradation of Aβ peptide via cathepsin D, triggering the intracellular accumulation of Aβ peptide [14] . Therefore, many primary therapeutic goals are targeted at reducing the metal-induced Aβ aggregation into toxic components. One of the therapeutic strategies is development of the agents that can chelate metal ions [18, 19] to prevent the metal ions from the interaction with Aβ peptide as well as to attenuate the metal-induced redox activity and neurotoxicity of the peptides.
Recently, a series of potential small molecule drugs, concerned with neurodegenerative disorders, were reported [20] . Among them, curcumin ( Fig. 1) , a natural product having potent antioxidant and antiinflammatory activities, is under development as a potential chemotherapeutic agent of cancer and neurodegenerative disorders [21, 22] . Previous studies have also shown that curcumin can interact with Aβ, thus inhibiting the Aβ aggregation and deposition [23] , even disrupting the existing plaques, and partially restoring the distorted neuritis [24, 25] . In addition, curcumin can readily chelate the metal ions, such as Cu 2 + , Zn 2 + , Al 3 + , Fe 3 + and Mn 2 + [26] [27] [28] [29] [30] [31] , to form the complexes, reducing the metal-induced Aβ neurotoxicity. Though curcumin has been demonstrated safe and efficient as a chemotherapeutic agent, its pharmaceutical role is still restricted because of its low aqueous solubility, inadequate tissue absorption and degradation at alkaline pH, which severely curtail its bioavailability [32, 33] . Because of those disadvantages of the curcumin, modification of the curcumin structure and development of the potential delivery systems have been suggested to improve the aqueous solubility, stability and bioavailability of the curcumin [34] [35] [36] . In addition, it is reported that metal-curcumin complexes have the protective roles against stress, free radical and neuronal damage [26, 28, 31] . Hence, new strategy concerning the roles of metal-curcumin complexes in AD treatment is very attractive.
Since curcumin can bind Al(III) to form three types of Al(III)-curcumin complexes in molar ratio of 1:2, 1:1, 2:1, as characterized by 27 Al nuclear magnetic resonance and mass spectroscopy as well as density functional theory calculation in our previous work [30] , we speculate that curcumin may have ability to block the interaction between Al(III) and Aβ 42 , and the formed Al(III)-curcumin complexes which are highly soluble [30] could be more effective in reducing the Aβ 42 fibrillation and neurotoxicity than curcumin alone.
In the present study, we used circular dichroism (CD) spectroscopy, thioflavin T (ThT) fluorescence, atomic force microscopy (AFM), Bradford and MTT assays to investigate the relationship among curcumin, Al(III) and Aβ 42 morphologies and its neurotoxicity. The relationship was rationalized on the molecular and cellular basis in the present work, and the Al(III)-curcumin complexes were demonstrated capable of reducing the fibrillation and neurotoxicity of Aβ 42 .
Materials and methods

Preparation of Aβ 42 aggregates
Aβ 42 was purchased from GL Biochem Ltd. (Shanghai, China). Firstly, Aβ 42 peptide was dissolved in hexafluoroisopropanol (HFIP) to a concentration of 1 mg/mL, and sonicated in water bath for 5 min and stood for 1 h at room temperature; then the Aβ 42 solution was separated into aliquots in microcentrifuge tubes, freeze-dried under high vacuum and stored at −20°C. Immediately prior to the use, the HFIP-treated Aβ 42 aliquots were dissolved in 0.2 M NH 3 ⋅H 2 O [13, 37] to the concentration of 2.0 mg/mL for 1 h at room temperature, and then diluted to 0.5 mg/mL with TBS (5 mM Tris, 20 mM NaCl), and adjusted to pH 7.4 by HCl. The final concentration of NH 4 + -contained ions in the Aβ 42 solution was 50 mM. The peptide solutions were then filtered through a 0.22-μm syringe filter removing any large species. For study of Al(III) and curcumin interaction with Aβ 42 , the previously prepared Aβ 42 solution were mixed with various volumes of 0.5 mM AlCl 3 
CD spectroscopy
CD spectrum of Aβ 42 was recorded by a Jasco spectropolarimeter with a quartz cell of 1 mm path length. 200 μL of the incubated samples was used for CD measurement. CD spectra were measured at wavelength from 190 to 250 nm with a scan speed of 100 nm/min and accumulation of five scans. A blank control (20 mM phosphate buffer, pH 7.4) was subtracted from the studied spectra.
ThT fluorescence assay
The fibrillation of Aβ 42 was evaluated by ThT fluorescence with a fluorescence spectrophotometer (FLS-920, Edinburgh Instruments). 200 μL of Aβ 42 solution incubated as described above was added into 800 μL ThT solution (15 μM ThT in 5 mM TBS, pH 7.4). The fluorescence of Aβ 42 sample in a quartz cuvette with the light-path of 1 cm was excited at wavelength of 450 nm and recorded at emission wavelength of 485 nm. The spectrum was scanned twice and subtracted by free ThT fluorescence. All fluorescence experiments were repeated three times and averaged along with standard deviation. The ThT fluorescence curves were fitted with a sigmoidal model using Sigmoidal Fit packaged in Origin 7.5 software. 2.5. AFM image 5 μL of above incubated sample was freshly collected and swiftly diluted to 5 μg/mL solution with TBS (5 mM Tris, 20 mM NaCl). 10 μL of the diluted sample was mounted onto the freshly cleaved mica for 5 min, gently rinsed with deionized water, and dried in vacuum overnight. Images were acquired under atmosphere using the silicon probe in a tapping mode packaged in multi-mode SPM Nanoscope IV system (Veeco Metrology Group, USA).
Bradford protein assay
Coomassie Brilliant Blue (CBB) staining is one of the popular methods for the protein analysis. The concentrations of the pre-incubated Aβ 42 samples were measured using Bradford assay. Briefly, 100 μL of each pre-incubated Aβ 42 sample was centrifuged at 16,000 g for 8 min at 4°C. 80 μL of the supernatant was diluted using 360 μL CBB-G250 solution and then incubated for 5 min at room temperature. The absorption at 595 nm (A 595 ) was measured by a Bio-Rad plate reader. The values were averaged from four parallel wells for each Aβ 42 sample and control (without Aβ 42 ). All experiments were run with three replicates.
Cell cultures and MTT assay
Cell cultures and MTT assay were performed as described elsewhere [38] . Briefly, PC12 cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% horse serum, 5% fetal bovine serum (FBS), 1% L-glutamine (3.6 mM), and 1% penicillin/streptomycin antibiotics in 5% CO 2 at 37°C. Cells were harvested from flasks and plated in 96-well polystyrene plates (Corning Inc., Corning, NY) with approximately 10,000 cells in 100 μL of medium per well. Cells were incubated at 37°C for 24 h to attach the plates. 50 μL of each pre-incubated Aβ 42 sample at given incubation time was diluted with fresh medium and added individually to the cell well. The final concentration of Aβ 42 in each culture well with or without Al(III) and curcumin was 1 μM. The same volume of medium was added into control cultures (only PC12 cells present). The cells were then incubated for additional 60 h at 37°C. At the end of incubation, the cell viability was determined by MTT assay. Firstly, the preincubated medium in each well was aspirated carefully, and then 100 μL fresh DMEM with 0.75 mg/mL thiazolyl blue tetrazolium bromide was added into each well. After incubation for additional 4 h at 37°C, the formed crystals were dissolved by addition of 150 μL DMSO each well with shaking for 15 min at room temperature. The absorbance at 490 nm was measured by a Bio-Rad multi-well assay plate reader and averaged by five replicated wells for each sample as well as control. Cell viability was calculated by the ratio of the absorbance of cells with Aβ 42 presence to that without Aβ 42 presence. Data were collected from three independent experiments. The standard deviations were analyzed by one-way ANOVA packaged in Origin 7.5 software.
Results
Impact of Al(III) and curcumin on the secondary structure and fibrillation of Aβ 42
To investigate curcumin effect on the Al(III)-induced conformational transition of Aβ 42 , CD spectroscopy was applied to observe the changes in secondary structures of the Aβ 42 at different concentrations of Al(III) and curcumin, after the samples were incubated for 3 days. As shown in Fig. 2 , the conformation conversion of Aβ 42 is inhibited by curcumin from a physiological unfolded random coil to a folded β-sheet, which is demonstrated by less negative band at 217 nm, when compared with that of Aβ 42 alone; while in the presence of Al(III), CD spectrum shows an increase in the negative band at 217 nm, which indicates a structural change into β-sheet. Intriguingly, when addition of curcumin into the Al(III)/Aβ 42 mixed samples, the spectrum appears a broad negative band around 206 nm which is attributed to the mixture of random coil, beta-sheet and alpha-helix structures. The results suggest that the formed Al(III)-curcumin complexes could prevent Aβ 42 from converting into a folded conformation more effectively than curcumin.
ThT fluorescence has been widely used to detect the β-sheet conformers and their aggregates of Aβ 42 [39, 40] . Therefore, in the present work, to examine the inhibitory effect of curcumin on Al(III)-induced Aβ 42 fibrillation, ThT fluorescence was used to detect the amyloid fibrils of Aβ 42 incubated with Al(III) in the absence or presence of curcumin. ThT fluorescence intensity of Aβ 42 alone shows initially a low plateau phase, called as lag phase during the first 2 days of incubation, and then increases from 2 to 5 days, and finally reaches to a high plateau after 5 days of incubation ( Fig. 3A-a) . In the presence of Al(III), the lag phases are shortened gradually as the concentration of Al(III) increased ( Fig. 3A-b , c, d, e), meanwhile, the slope of the exponential phase and the fluorescence intensity of the final plateau considerably increase in a dose-dependent manner. In contrast, the amyloid formation of Aβ 42 is somewhat suppressed by curcumin, as demonstrated by the decrease in both the corresponding fluorescence intensity and the slope of the exponential phase (Fig. 3B ). Furthermore, when incubation of Aβ 42 in the presence of 10 μM curcumin with various concentration of Al(III) ranging from 0 to 20 μM, the significantly lower fluorescence intensity of Aβ 42 is shown in Fig. 3C , compared with those without curcumin. During 2 to 6 days of incubation, it is surprising to find that the Aβ 42 sample incubated with Al(III)/curcumin mixture at molar ratio of 1:1 has a reduction in the fluorescence intensity in Fig. 3D , compared with that in the presence of curcumin only. These findings indicate that curcumin has ability to prevent Aβ 42 from the Al(III)-induced fibrillation, and the Al(III)-curcumin complexes formed in molar ratio of 1:1 might have stronger ability to inhibit the fibrillation of Aβ 42 (Fig. 3D ).
Morphologies of aggregates detected by AFM
AFM experiments were carried out to observe the morphologies of Aβ 42 incubated in the presence or absence of Al(III) and curcumin from 1 to 5 days (Fig. 4) . In Fig. 4A , the control sample (Aβ 42 alone) shows a characteristic fibrillation process which is in agreement with above results. After incubation for 1 day (Fig. 4A-day 1) , the small oligomers are observed in the control sample. Those oligomers prolong into the protofibrils or fibrils after 3 or 5 days of incubation ( Fig. 4A -day 3 and day 5). When co-incubation of Aβ 42 with Al(III), the amount of oligomers after incubation for 1 day (Fig. 4B-day 1 ) and the fibrils after incubation for 3 days or 5 days ( Fig. 4B -day 3 and day 5) increase, which is consistent with CD results (Fig. 2) and ThT fluorescence results (Fig. 3) . Intriguingly, in the presence of 10 μM curcumin, the oligomeric aggregates decrease after incubation for 1 day (Fig. 4C-day 1 ). Further 2 days or 4 days of incubation, the Aβ 42 assemble into the amorphous aggregates dramatically instead of the protofibrils or fibrils (Fig. 4C -day 3 and day 5). To substantiate the inhibitory effect of curcumin on the Al(III)-induced Aβ 42 fibril formation, 10 μM curcumin was added into the Aβ 42 samples in the presence of 10 μM Al(III), as seen from Fig. 4D , the amount of oligomers is substantially less than that in the control sample ( Fig. 4Dday 1) . Besides, during further incubation, only a few amorphous aggregates instead of fibrils are observed ( Fig. 4D -day 3 and day 5). Evidently, the morphologies of Aβ 42 aggregates are very different between presence and absence of curcumin and Al(III) during the incubation. These findings clearly demonstrate that curcumin shows a strongly inhibitory effect on the Al(III)-induced fibrillation of Aβ 42 , and the formed Al(III)-curcumin complexes promote the formation of amorphous aggregates of Aβ 42 , but prevent their further development into the fibrillar amyloids.
Peptide analysis by the Bradford assay
To determine the concentration of the un-aggregated peptide in each incubated sample, Bradford assay was used to measure the peptide concentration in the supernatants of the pre-incubated Aβ 42 samples. The peptide is quantified based on the absorbance of peptide-Coomassie Brilliant Blue (CBB) complexes at wavelength of 595 nm. In Fig. 5 , curve-a shows the absorbance of Aβ 42 -CBB complex without Al(III) and curcumin presence. The absorbance decreases gradually as the incubation time increased, which implies that the Aβ 42 monomers may assemble into the fibrils continuously during incubation, agreeable with AFM result in Fig. 4A . The curve-b, curve-c and curve-d in Fig. 5 show Al(III), curcumin and their complexes how to affect the absorbance of the Aβ 42 -CBB complexes at 595 nm, respectively. A 595 values in the presence of Al(III) (curve-b in Fig. 5 ) are lower than that of Aβ 42 alone, indicating that Al(III) accelerates the formation of Aβ 42 fibrils or fibril plaques, agreeable with AFM result in Fig. 4B . When incubation of Aβ 42 with curcumin presence for 2 or 3 days, the absorbance of the Aβ 42 -CBB complexes is the lowest (curve-c in Fig. 5 ), revealing that there exist the least un-aggregated peptides in the samples during the incubation period; while in the presence of both curcumin and Al(III), the absorbance of the Aβ 42 -CBB complexes is always the highest (curve-d in Fig. 5 ), which means that more unaggregated peptides exist in the incubated samples.
Neurotoxicity of Aβ 42 in the presence or absence of curcumin and Al(III)
We determined the neurotoxicity of the Aβ 42 toward PC12 cells with or without curcumin and Al(III) presence by MTT assay. Fig. 6A demonstrates that when incubation of PC12 cells with 250 nM curcumin or Al(III), respectively, few reduction in the viability of PC12 cells is observed as compared with that of normal control group (DMEM without Aβ 42 , Al(III) and curcumin presence). Similar results are observed when coincubation of PC12 cells with curcumin and Al(III) (Fig. 6A) . In contrast, when further co-incubation of PC12 cells with the Aβ 42 samples preincubated for 1 day at 37°C already, the PC12 cell viability is reduced by 37%, which indicates that the pre-incubated Aβ 42 exhibits the substantial neurotoxicity (Fig. 6A ). On the other hand, when further co-incubation of PC12 cells with the Aβ 42 sample pre-incubated with different concentration of Al(III), the Aβ 42 aggregates with low or high concentration of Al(III) presence attenuate significantly the cell viability to 53 ±0.8% or 46± 1.4%, respectively, compared with the cell viability of 63 ±2.4% without Al(III) presence. The results indicate that Al(III) promotes substantially the neurotoxicity of Aβ 42 dose-dependently ( Fig. 6A ). However, when further co-incubation of PC12 cells with the Aβ 42 sample pre-incubated with curcumin for 1 day, Aβ 42 shows a decrease in neurotoxicity (Fig. 6A) . Intriguingly, when further co-incubation of PC12 cells with the Aβ 42 (40 μM) sample pre-incubated with curcumin (10 μM) and Al(III) (10 μM) for 1 day, curcumin shows a protection against the Aβ 42 neurotoxicity promoted by Al(III), as shown in Fig. 6A . It is worth noticing that the formed Al(III)-curcumin complexes attenuate the Aβ 42 toxicity more substantially than curcumin alone (Fig. 6A) , and the Al(III)curcumin complex formed at [Al(III)]/[curcumin] molar ratio of 1:1 attenuate the Aβ 42 toxicity in a dose-dependent manner as well. Fig. 6B shows the dependence of PC12 cells viability on the Aβ 42 pre-incubated from 1 to 5 days at 37°C in the presence or absence of Al(III) and curcumin. Though the Aβ 42 neurotoxicity induced by Al(III) (Fig. 6B-b) is higher than that of Aβ 42 alone (Fig. 6B-a) and is attenuated by curcumin ( Fig. 6B-d) , the neurotoxicity of Aβ 42 with or without Al(III) and curcumin presence are decreased time-dependently (Fig. 6B) , which identifies the assumption in which the soluble oligomers are the dominant pathological entities in AD [4] . Comparison of the morphology of Aβ 42 with its neurotoxicity, we suppose that Al(III) promotes the formation of Aβ 42 oligomers which have substantial toxic to PC12 cells, whereas curcumin induces the formation of amorphous Aβ 42 aggregates, inhibiting the formation of Aβ 42 oligomers, therefore attenuating the Aβ 42 toxicity. On the other hand, during further incubation of Aβ 42 , the formed Aβ 42 oligomers assemble into the fibrils which are lower toxic than the oligomeric species, which result in an attenuation of the Aβ 42 neurotoxicity. Intriguingly, the formed Al(III)-curcumin complexes inhibit the oligomerization and the fibrillation of Aβ 42 , mean while, induce the formation of amorphous aggregates, thus decreasing substantially the cell death. β-sheet-rich structure which is demonstrated by the most negative band at 217 nm. However, the band at 217 nm becomes less negative during further 3 days of incubation when the concentration of curcumin is equal to that of Al(III) of 10 μM, which indicates that Aβ 42 experiences gradually a structural transition from β-sheet structure to random coil one. The disaggregation of the preformed fibrils is also demonstrated by ThT fluorescence analysis. Fig. 7B shows that after one more day of incubation of the pre-incubated sample, the ThT fluorescence intensity reaches to a high plateau in the absence of curcumin; while in the presence of Al(III) and curcumin at molar ratio of 1:1, the fluorescence intensity of the pre-incubated Aβ 42 sample is decreased, which suggests that the fibrillar growth of Aβ 42 is inhibited and the pre-formed β-sheetrich fibrils is disassembled. The remodeled aggregates are also observed by AFM images (in Fig. 7C ). In the presence of curcumin, the preformed Aβ 42 fibrils (in Fig. 7C-I) are noticeably disassembled and remodeled into the amorphous aggregates (in Fig. 7C-III) , instead of further assembled into the fibril plaques (in Fig. 7C -II) in the absence of curcumin. Above results suggest that curcumin succeeds in converting the Al(III)-induced βsheet-rich fibrils into the unfolded amorphous aggregates which is low toxic to PC12 cells (Fig. 7D ).
Discussion
Effect of curcumin and Al(III) on Aβ 42 fibrillation
In combinations of the results from circular dichroism spectroscopy, thioflavin T fluorescence, atomic force microscopy, Bradford and MTT assays, the vitro experiments reported in this study provide an unique insight into the role of Al(III), curcumin, particularly Al(III)curcumin complex affecting the Aβ 42 morphologies and neurotoxicity. Our previous work [30] As shown in Fig. 3D , the aggregation and fibrillation kinetics of Aβ 42 appear typically sigmoidal [41] . The results show clearly that Al(III) accelerate the random coil Aβ 42 monomers aggregating into the β-sheet fibrils. Al(III) is known to bind the \COO\ group in Glu and Asp residues and the \OH group in Ser and Tyr residues [42] . The amino acid residues bound with Al(III) are present in both hydrophilic motifs (sequence of 1-16) and hydrophobic motifs (sequence of [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] in Aβ 42 , more than that bound with Zn(II) and Cu(II) which coordinate dominantly the N-terminal sequence (sequence of 1-16) of Aβ [10, 43] . On one hand, binding of Al(III) to the carboxylic groups in Aβ peptide would neutralize the electrostatic repulsions which prevent the self-interactions between two Aβ monomers [10] , on the other hand, Al(III) might act as a "disulfide linkage" to link two Aβ molecules [30, 44] , leading to the distance between two Aβ molecular chains reduced, thus promoting the formation of inter-H-bonds of Aβ; the hydrophilic residues of Aβ buried into the interior of the molecule, and the hydrophobic residues exposed out the exterior of the molecule [13] . As a consequence of Aβ 42 binding with Al(III), the hydrophobic motifs may assemble together to form the folded Aβ 42 aggregates and the fibrils with a lowered free energy [45] . However, when curcumin presents, the strong interaction between Al(III) and curcumin blocks the interaction between Al(III) and Aβ 42 and inhibits the ordered fibrillation of Aβ 42 . Curcumin is a linear flat molecule (Fig. 1 ) like those amyloid dyes, such as Congo red and thioflavin-T [40, 46] . The linear flat structure of curcumin benefits its diketo group binding the protein [47] . Moreover, these linear dye molecules bind parallel to the long axis of the fibril surface in the grooves formed by the side-chain ladders rich in aromatic amino acids [40] . Besides, in curcumin molecule, there are many active \OH groups that are capable of interacting with N or O atoms in the amino residues of Aβ 42 , therefore, curcumin like Congo red and thioflavin-T may insert itself into the β-sheets fibrils of Aβ 42 [40, 48] , and its steric hindrance caused by the rigid aromatic frame in curcumin might block the formation of the inter-hydrogen-bonding of Aβ 42 molecules, leading to the formation of loosely and less ordered Aβ 42 structure. Interestingly, the formed Al(III)-curcumin complexes can even remodel the preformed Aβ 42 fibrils into the low neurotoxic amorphous aggregates, which is maybe ascribed to the water solubility of the Al(III)-curcumin complex having the diplex functions via both hydrophobic curcumin and hydrophilic Al(III) to interact with the Aβ 42 fibrils, leading to the disassembly of the ordered Aβ 42 fibrils into the amorphous aggregates. The Al(III)curcumin complex, therefore, could be considered as a inhibitor of the oligomeric intermediates and a stabilizer of the amorphous aggregates by inhibiting the subsequent fibrillar growth of Aβ 42 , meanwhile, it could be used as a disintegrator to remold the Aβ 42 fibrils into the amorphous aggregates.
Correlation between Aβ 42 aggregate conformation, morphology and neurotoxicity
In this work, we attempted to correlate the Aβ 42 neurotoxicity with its aggregate morphology for well understanding the biological mechanism and developing the therapeutics for AD. It is found that during first 3 days of incubation, the Aβ 42 aggregates which consist mainly of the partially folded oligomers and protofibrils, have marked toxicity on PC12 cells. However, after long time of incubation, the elongated Aβ 42 aggregates which consist mainly of orderly aligned fibrils and fibril plaque show low neurotoxicity. This observation identifies the assumption in which the soluble oligomers are main pathological entities in AD [4] . Some mechanisms have been proposed to explain the toxicity of Aβ oligomers, for instance, the destabilization of cell membrane, the disruption of calcium homeostasis, and the increase of oxidative stress, while the death of cells is most likely triggered via multiple toxicity pathways [49] . In the presence of Al(III), the formation of partially folded Aβ 42 oligomers and protofibrils are accelerated, leading to the strong neurotoxicity of the Aβ 42 , whereas, curcumin induces the formation of amorphous Aβ 42 aggregates, and inhibits the formation of Aβ 42 oligomers, therefore attenuating the Aβ 42 toxicity. On the other hand, in the presence of curcumin, the Al(III)-induced fibrillation of Aβ 42 is inhibited, with the formation of the low toxic amorphous aggregates which are mainly in random coil conformation. In addition, the preformed Aβ 42 fibrils are remodeled into the low toxic amorphous aggregates by the formed Al(III)-curcumin complexes instead of into the toxic fibril precursors which enhance the neurotoxicity in AD.
Potential of Al(III)-curcumin complex as a novel agent for AD treatment
A number of therapeutic strategies targeting AD have been proposed, for instance, decreasing the production of Aβ, cleaning the existing aggregates from brain or blood, inhibiting the physiologic conformational change of Aβ to its pathological β-sheet form and blocking the formation of oligomers, protofibrils, or fibrils [50, 51] . Up to date, the available therapies can merely provide AD symptomatic relief, and the issue is still fatal. Attention has been paid particularly to curcumin for long time because the regular diet of curcumin is one of the reasons to reduce the risk of AD in Indian [52] . Although curcumin has been demonstrated safe and capable of passing through the blood-brain barrier [52] , its pharmacological application is still limited because of low solubility and inadequate bioavailability. In this work, the formed Al(III)-curcumin complexes can reduce the Aβ 42 fibrillation and neurotoxicity more effectively than curcumin alone. The strong ability of Al(III)-curcumin complex to inhibit the oligomerization and fibrillation of Aβ 42 may be due to the high solubility of this complex and its strong interaction with Aβ 42 . As reported in our previous work [30] , curcumin can chelate Al(III) ions stably via its active enol-H groups to form three types of complexes with Al(III) in molar ratios of 1:2, 1:1 and 2:1 [30] , and the Al(III) in Al(III)-curcumin complexes not only chelates curcumin, but also interacts with water molecules, which lead to the formed Al(III)curcumin complexes more hydrophilic. The soluble Al(III)-curcumin complexes may bind to Aβ 42 by both \OH groups in curcumin and active Al(III), allowing its interaction more efficient than curcumin alone.
Although aluminum element was reported to act as a neurological toxicant and provoke the embryonic and fetal toxicity on animal and human after gestational exposure [53] , it still remains unclear whether long-term exposure or accumulation of even small amounts of aluminum in human body can result in the clinically toxic effects [54] . Normally, aluminum is absorbed via the gastrointestinal tract and excreted primarily by kidneys or bile. Though its biological or physiological roles are still unclear, aluminum is able to make use of transferrin, an iron-carried plasma protein, to across the blood-brain barrier into the brain tissue [55] . Many aluminum-contained drugs such as antacids and some buffered analgesics are ingested over a long period of time and considered to be sufficiently safe for sale over-the-counter (OTC) [56] . In addition, aluminum salts are also used as the pharmaceutical excipients or adjuvants in the preparation of a number of vaccines, toxoids and allergen injectants. On the basis of the above discussion, Al(III)-curcumin complex, in the appropriate dose and the complex form, is maybe worth potentially developing as a therapy agent against the neurodegenerative disorders in the future.
